Notable Labs

Notable Labs EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Notable Labs (NTBLQ) as of Nov 10, 2026 is -14.66 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -32.85 M USD — a change of -55.38% (higher).

EBITDA

-14.66 MUSD

YoY

-55.38%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Notable Labs is 2023 -14.66 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Notable Labs was 2022 -32.85 M USD. It decreases by -55.38% higher compared to the previous year.

The Notable Labs EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2016
-16.15 M USD
Jan 1, 2017
-10.50 M USD
Jan 1, 2018
-21.25 M USD
Jan 1, 2019
-20.08 M USD
Jan 1, 2020
-24.48 M USD
Jan 1, 2021
-30.00 M USD
Jan 1, 2022
-32.85 M USD
Jan 1, 2023
-14.66 M USD
The Notable Labs EBITDA history
YEAREBITDAYoY
-14.66 MUSD-55.38%
-32.85 MUSD+9.50%
-30.00 MUSD+22.55%
-24.48 MUSD+21.91%
-20.08 MUSD-5.51%
-21.25 MUSD+102.38%
-10.50 MUSD-34.98%
-16.15 MUSD+9.49%
-14.75 MUSD+0.75%
-14.64 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Notable Labs is -14.66 M USD in 2023.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Notable Labs changed from -32.85 M USD to -14.66 M USD, representing a -55.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Notable Labs

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Notable Labs